BCM
CYTK icon

Bayesian Capital Management’s Cytokinetics CYTK Stock Holding History

Bayesian Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,274
Closed -$1.75M – 754
2024
Q2 		$1.75M Buy
32,274
+1,600
+5% +$96.6K 0.2% 135
2024
Q1 		$2.15M Sell
30,674
-8,000
-21% -$619K 0.21% 141
2023
Q4 		$3.23M Buy
+38,674
New +$1.4M 0.34% 68
2023
Q2 		– Sell
-15,124
Closed -$532K – 838
2023
Q1 		$532K Buy
15,124
+5,924
+64% +$242K 0.07% 375
2022
Q4 		$422K Buy
+9,200
New +$396K 0.06% 398
2022
Q3 		– Sell
-5,900
Closed -$232K – 755
2022
Q2 		$232K Buy
+5,900
New +$238K 0.04% 573
2017
Q1 		– Sell
-13,100
Closed -$159K – 468
2016
Q4 		$159K Buy
+13,100
New +$139K 0.04% 543

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bayesian Capital Management's CYTK Position: Q3 2024 in Review

Bayesian Capital Management sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 32,274 shares — an estimated $1.75M sold.

Bayesian Capital Management first reported a position in CYTK in Q4 2016 and held it in 7 quarters. The position peaked at $3.23M in Q4 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Bayesian Capital Management reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 32,274 Cytokinetics shares in Q3 2024, an estimated $1.75M.
  • Bayesian Capital Management first reported a position in Cytokinetics in Q4 2016 and held it in 7 quarters.
  • Bayesian Capital Management's Cytokinetics position peaked at $3.23M in Q4 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.